LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models have been published, but few have been tested…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing…
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device…
November 13, 2025 18:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai…
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the…
November 03, 2025 16:45 ET | Source: Fulcrum Therapeutics, Inc. ― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell…
Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance…
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…